• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Design an access-based network to reduce costs

Article

Innovative payers are starting to look differently at how they build their pharmacy network, using a bottom-up approach to network design.

Access-based network design is an approach that can result in a significant reduction in prescription drug costs while ensuring that members maintain access to a network pharmacy. While the exact process for building an access-based network can vary based on a state's any-willing-provider laws and whether or not the plan is subject to such laws under ERISA, the basic approach follows a few principles:

Set an access standard. Quantify what access standard you want to provide for your members. For example, you may decide that you want to set a standard of 90% of your members living within six miles of a network pharmacy. Once you have quantified this access standard, your objective is to minimize costs while ensuring that the standard is achieved.

Define the prize. Let pharmacies know the number of pharmacies expected in the network. Ensure that pharmacies know their downside risk by basing reimbursement on effective rate guarantees or a cost-plus pricing methodology. By understanding downside risk, pharmacies can be more aggressive in their pricing.

Compete. Have pharmacies compete against each other to get into the network. Allow pharmacies to submit a second, more aggressive bid in order to be a preferred pharmacy that is granted a small copay advantage versus other pharmacies in the network.

Communicate. Announce the network and let members know that they have the option of lower copays at the preferred pharmacies in the network.

Related Videos
Video 3 - "In-Office Procedures, Over-the-Counter Options, Treatment Delays, and Costs"
Video 6 - "Safety Analysis and Interpreting Results from MAJIC-PV"
Video 5 - "Key Findings from MAJIC-PV"
Video 2 - "Traditional Treatment of Demodex Blepharitis, FDA approval, and Lotilaner Ophthalmic Solution, 0.25%"
Gabriela Hobbs, MD, an expert on polycythemia vera
Gabriela Hobbs, MD, and Timothy Mok, PharmD, BCPS, BCOP
Video 1 - "Demodex Blepharitis: Prevalence, Symptoms, Quality of Life Impact, and Diagnosis"
Video 2 - "The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance"
Video 1 - "Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera"
Related Content
© 2024 MJH Life Sciences

All rights reserved.